Peripheral Lymphocytes in Primary Liver Cancers: Elevated NK and CD8+ T Cells and Dysregulated Selenium Metabolism.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101596414 Publication Model: Electronic Cited Medium: Internet ISSN: 2218-273X (Electronic) Linking ISSN: 2218273X NLM ISO Abbreviation: Biomolecules Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, 2011-

Carcinoma, Hepatocellular*/metabolism ; Selenium*/metabolism ; Liver Neoplasms*/metabolism; Humans ; Proteomics ; CD8-Positive T-Lymphocytes ; Killer Cells, Natural

Peripheral blood lymphocytes (PBLs), which play a pivotal role in orchestrating the immune system, garner minimal attention in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The impact of primary liver cancers on PBLs remains unexplored. In this study, flow cytometry facilitated the quantification of cell populations, while transcriptome of PBLs was executed utilizing 10× single-cell sequencing technology. Additionally, pertinent cases were curated from the GEO database. Subsequent bioinformatics and statistical analyses were conducted utilizing R (4.2.1) software. Elevated counts of NK cells and CD8+ T cells were observed in both ICC and HCC when compared to benign liver disease (BLD). In the multivariate Cox model, NK cells and CD8+ T cells emerged as independent risk factors for recurrence-free survival. Single-cell sequencing of PBLs uncovered the downregulation of TGFβ signaling in tumor-derived CD8+ T cells. Pathway enrichment analysis, based on differential expression profiling, highlighted aberrations in selenium metabolism. Proteomic analysis of preoperative and postoperative peripheral blood samples from patients undergoing tumor resection revealed a significant upregulation of SELENBP1 and a significant downregulation of SEPP1. Primary liver cancer has a definite impact on PBLs, manifested by alterations in cellular quantities and selenoprotein metabolism.

Innovation (Camb). 2021 Jul 01;2(3):100141. (PMID: 34557778)
Cell. 2021 Feb 4;184(3):792-809.e23. (PMID: 33545035)
Biomark Res. 2021 Aug 21;9(1):64. (PMID: 34419152)
Proc Nutr Soc. 2010 Aug;69(3):300-10. (PMID: 20576203)
Hepatol Res. 2014 Jun;44(6):639-50. (PMID: 23701406)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Clin Immunol. 2023 Nov;256:109770. (PMID: 37717672)
Front Immunol. 2019 Jul 19;10:1719. (PMID: 31379886)
Immunity. 2021 Aug 10;54(8):1728-1744.e7. (PMID: 34343498)
ACS Appl Mater Interfaces. 2019 Dec 11;11(49):45404-45415. (PMID: 31736295)
J Hepatol. 2021 May;74(5):1212-1224. (PMID: 33545267)
Nature. 2002 Dec 19-26;420(6917):860-7. (PMID: 12490959)
Nat Commun. 2021 Jul 2;12(1):4091. (PMID: 34215748)
Science. 2016 Dec 2;354(6316):1160-1165. (PMID: 27789795)
Nat Mater. 2017 Nov;16(11):1155-1161. (PMID: 29035356)
Nat Rev Immunol. 2020 Feb;20(2):128-136. (PMID: 31591533)
Cell. 2020 Oct 15;183(2):377-394.e21. (PMID: 32976798)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Annu Rev Med. 2022 Jan 27;73:267-278. (PMID: 34606324)
Front Immunol. 2022 Jun 27;13:849958. (PMID: 35833139)
Nat Methods. 2019 Dec;16(12):1289-1296. (PMID: 31740819)
Front Immunol. 2023 Jan 13;13:1091103. (PMID: 36713363)
Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021)
Clin Res Hepatol Gastroenterol. 2012 Aug;36(4):345-51. (PMID: 22902352)
Cell. 2021 Jan 21;184(2):404-421.e16. (PMID: 33357445)
Biomaterials. 2019 Oct;219:119377. (PMID: 31374478)
Adv Sci (Weinh). 2020 May 18;7(13):2000224. (PMID: 32670760)
Nature. 2017 Jan 18;541(7637):321-330. (PMID: 28102259)
Cell. 2017 Jun 15;169(7):1342-1356.e16. (PMID: 28622514)
F1000Res. 2021 Sep 28;10:979. (PMID: 35814628)
Cancer Discov. 2022 Jul 6;12(7):1718-1741. (PMID: 35412588)
BMC Gastroenterol. 2023 Jul 12;23(1):234. (PMID: 37438735)

82373313 National Natural Science Foundation of China; 82072677 National Natural Science Foundation of China; 82072672 National Natural Science Foundation of China; 2022J011428 Natural Science Foundation of Fujian

Keywords: SELENBP1; SEPP1; peripheral blood lymphocytes; primary liver cancer

H6241UJ22B (Selenium)

Date Created: 20240224 Date Completed: 20240226 Latest Revision: 20240227

20240227

PMC10886987

10.3390/biom14020222

38397459